Gene-specific fluorescence in-situ hybridization analysis on tissue microarray to refine the region of chromosome 20q amplification in melanoma

Melanoma Research

Volumn 17, Issue 1, 2007, Pages 37-41

  Koynova, Denitsa K ^a   Jordanova, Ekaterina S ^c   Milev, Angel D ^b   Dijkman, Remco ^c   Kirov, Krassimir S ^b   Toncheva, Draga I ^a   Gruis, Nelleke A ^c  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b National Oncology Center Bulgaria   (Bulgaria)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

20q chromosome arm; Cutaneous malignant melanoma; Fluorescence in situ hybridization; Tissue microarray; Tumor progression

Indexed keywords

AURORA A KINASE;

ARTICLE; AURORA A KINASE GENE; CANCER GENETICS; CANCER GROWTH; CENTROMERE; CHROMOSOME 20Q; CONTROLLED STUDY; CYP24 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE PROBE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYBL2 GENE; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SKIN METASTASIS; TISSUE MICROARRAY; ZNF217 GENE;

CENTROMERE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 20; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 33846404540     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3280141617     Document Type: Article

References (28)

1. Micheli A, Mugno E, Krogh V, Quinn MJ, Coleman M, Hakulinen T, et al. EUROPREVAL Working Group. Cancer prevalence in European registry areas. Ann Oncol 2002; 13:840-865.
2. Rager EL, Bridgeford EP, Ollila DW. Cutaneous melanoma: update on prevention, screening, diagnosis, and treatment. Am Fam Physician 2005; 72:269-276.
3. Balazs M, Adam Z, Treszl A, Begany A, Hunyadi J, Adany R. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46:222-232.
4. Wiltshire RN, Dennis TR, Sondak VK, Meltzer PS, Trent JM. Application of molecular cytogenetic techniques in a case study of human cutaneous metastatic melanoma. Cancer Genet Cytogenet 2001; 131:97-103.
5. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163:1765-1770.
6. Pirker C, Holzmann K, Spiegl-Kreinecker S, Elbling L, Thallinger C, Pehamberger H, et al. Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res 2003; 13:483-492.
7. Namiki T, Yanagawa S, Izumo T, Ishikawa M, Tachibana M, Kawakami Y, et al. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet 2005; 157:1-11.
8. Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, et al. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 2003; 201:603-608.
9. Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004; 23:5616-5623.
10. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004; 64:8534-8540.
11. Glatz-Krieger K, Pache M, Tapia C, Fuchs A, Savic S, Glatz D, Mihatsch M, Meyer P, et al. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch 2006 449:328-333.
12. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6:1833-1839.
13. Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, et al. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res 2002; 62:6803-6807.
14. Watanabe T, Imoto I, Katahira T, Hirasawa A, Ishiwata I, Emi M, et al. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers. Jpn J Cancer Res 2002; 93:1114-1122.
15. Weiss MM, Snijders AM, Kuipers EJ, Ylstra B, Pinkel D, Meuwissen SG, et al. Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol 2003; 200:320-326.
16. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10:2065-2071.
17. TNM classification of malignant tumors. 5th ed. UICC; Sobin LH, Wittekind Ch, editors. New York, New York: Wiley-Liss, Inc. 1997.
18. Haralambieva E, Kleiverda K, Mason DY, Schuuring E, Kluin PM. Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 2002; 198:163-170.
19. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000; 27:85-94.
20. Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003; 63:1179-1182.
21. Höglund M, Gisselsson D, Hansen GB, White VA, Sall T, Mitelman F, et al. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004; 108:57-65.
22. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004; 164:193-203.
23. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62:3200-3206.
24. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 1998; 95:8703-8708.
25. Rooney PH, Boonsong A, McFadyen MC, McLeod HL, Cassidy J, Curran S, et al. The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol 2004; 204:282-288.
26. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25:144-146.
27. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20:189-193.
28. Barks JH, Thompson FH, Taetle R, Yang JM, Stone JF, Wymer JA, et al. Increased chromosome 20 copy number detected by fluorescence in-situ hybridization (FISH) in malignant melanoma. Genes Chromosomes Cancer 1997; 19:278-285.